- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | Jyong Biotech Ltd.: Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates | 2 | GlobeNewswire (USA) | ||
| 23.07. | Jyong Biotech pursues global licensing partnerships for BPH drug | 3 | Investing.com | ||
| 23.07. | Jyong Biotech Ltd.: Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships | 317 | GlobeNewswire (Europe) | New Taipei City, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development... ► Artikel lesen | |
| 02.07. | Jyong Biotech presents drug candidate at BIO 2026 convention | 1 | Investing.com | ||
| 15.05. | Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 | 2 | GlobeNewswire (USA) | ||
| 15.05. | Jyong Biotech Ltd. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 27.03. | Jyong Biotech Ltd.: Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 | 350 | GlobeNewswire (Europe) | New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development... ► Artikel lesen | |
| 12.02. | Jyong Biotech Ltd.: Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market ... | 353 | GlobeNewswire (Europe) | - Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value... ► Artikel lesen | |
| JYONG BIOTECH Aktie jetzt für 0€ handeln | |||||
| 30.01. | Jyong Biotech Ltd.: Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value | 355 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 19.12.25 | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | 596 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| 04.12.25 | Jyong Biotech Ltd.: Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market Entry | 394 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 24.11.25 | Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS Drugs | 522 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 20.11.25 | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes | 466 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 9,370 | +2,74 % | Novavax: Citigroup bleibt bei Verkauf - der Rückschlag kommt zur Unzeit | ||
| INOVIO PHARMACEUTICALS | 0,702 | -17,47 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,560 | +0,26 % | InflaRx N.V.: InflaRx Announces November Investor Events | ||
| INTELLIA THERAPEUTICS | 11,720 | +0,51 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026 | ||
| EDITAS MEDICINE | 2,610 | +0,77 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,320 | -4,19 % | 1,9 Milliarden US-Dollar für verletzte Nerven: Warum Axogen, Integra und NurExone drei Reparaturprinzipien verfolgen | ||
| GERON | 0,827 | -5,35 % | XFRA GON: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGERON CORP. (DEL.)... ► Artikel lesen | |
| IBIO | 0,723 | +0,49 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| IMMUNITYBIO | 7,750 | -1,90 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 6,565 | -0,30 % | Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting | IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and... ► Artikel lesen | |
| MYRIAD GENETICS | 5,930 | -0,24 % | Myriad Genetics presents data on cancer recurrence detection test | ||
| MANNKIND | 3,121 | +2,19 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 11,205 | -5,64 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| IMMUNIC | 7,068 | +5,43 % | EQS-News: Immunic AG: Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026 | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
29.10.2026 / 11:30 CET/CEST
The issuer... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 8,250 | -38,34 % | Iovance Biotherapeutics Inc. - IOVA: weißer Rauch bei Lungenkrebs-Daten? | Intraday Trade? Rekordumsatz in Q2 bei Iovance Biotherapeutics. Lifileucel-Therapie mit Mega-Marktpotenzial! Vorbörsliches Gap Up! Iovance Biotherapeutics (IOVA) - US4622601007 Rückblick Nach einer... ► Artikel lesen |
JYONG BIOTECH LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,020 (+1,06 %) liegt der Kurs bei 1,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JYONG BIOTECH LTD finden Sie auf Wallstreet Online.